Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: a systematic review
Author:
Publisher
Elsevier BV
Subject
Hematology
Reference26 articles.
1. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management;Rajkumar;Am J Hematol,2020
2. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study;Attal;Lancet,2019
3. Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT): Results of the Randomized Phase III Trial SWOG S0777
4. Carfilzomib, lenalidomide, and dexamethasone vs lenalidomide and dexamethasone in patients (Pts) with relapsed multiple myeloma: interim results from ASPIRE, a randomized, open-label, multicenter phase 3 study;Stewart;Blood,2014
5. Analysis of control arm quality in randomized clinical trials leading to anticancer drug approval by the US Food and Drug Administration;Hilal;JAMA Oncol,2019
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Use of suboptimal control arms in randomized clinical trials of investigational cancer drugs in China, 2016–2021: An observational study;PLOS Medicine;2023-12-12
2. Control Groups in RCTs Supporting Approval of Drugs for Systemic Rheumatic Diseases, 2012-2022;JAMA Network Open;2023-11-22
3. Reporting of adverse events of treatment interventions in multiple myeloma: an overview of systematic reviews;Annals of Hematology;2023-11-08
4. Randomised controlled trials evaluating anticancer therapies in haematological cancers: an overview of global research activity;ecancermedicalscience;2023-08-06
5. Multiple myeloma: challenges with deciding the optimal sequencing strategy;Frontiers in Pharmacology;2023-07-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3